Hubei Biocause Pharmaceutical Co., Ltd. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was CNY 651.78 million compared to net income of CNY 274.05 million a year ago. Basic loss per share from continuing operations was CNY 0.13 compared to basic earnings per share from continuing operations of CNY 0.06 a year ago.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
1.73 CNY | +0.58% |
|
-1.70% | -39.08% |
Jul. 09 | Biocause Pharmaceutical's Insurance Arm Logs 25 Billion Yuan in Annual Insurance Premium | MT |
Jun. 17 | Biocause Pharma Plans Buyback of Up to 100 Million Yuan Shares | MT |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-39.08% | 1.18B | |
+9.36% | 77.41B | |
+12.35% | 52.64B | |
+10.95% | 52.19B | |
+26.37% | 48.49B | |
+18.86% | 44.26B | |
+23.27% | 39.65B | |
+16.44% | 33.1B | |
+43.61% | 29.62B | |
-8.64% | 27.43B |
- Stock Market
- Equities
- 000627 Stock
- News Hubei Biocause Pharmaceutical Co., Ltd.
- Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023